Here, we apply a novel gene expression platform in sequential formalin-fixed paraffin-embedded samples from nonhuman primate (NHP) renal transplants. We analyzed 34 previously described gene transcripts related to AMR in humans in 197 archival NHP samples, including 102 from recipients that developed chronic AMR, 80 from recipients without AMR, and 15 normal native nephrectomies. Three endothelial genes (VWF, DARC, and CAV1), derived from 10-fold cross-validation receiver operating characteristic curve analysis, demonstrated excellent discrimination between AMR and non-AMR samples (area under the curve = 0.92). This three-gene set correlated with classic features of AMR, including glomerulitis, capillaritis, glomerulopathy, C4d deposition, and DSAs (r = 0.39-0.63, p < 0.001). Principal component analysis confirmed the association between three-gene set expression and AMR and highlighted the ambiguity of v lesions and ptc lesions between AMR and T cell-mediated rejection (TCMR). Elevated three-gene set expression corresponded with the development of immunopathological evidence of rejection and often preceded it. Many recipients demonstrated mixed AMR and TCMR, suggesting that this represents the natural pattern of rejection. These data provide NHP animal model validation of recent updates to the Banff classification including the assessment of molecular markers for diagnosing AMR.
Introduction
RNA transcript analysis has the potential for precise, objective, and mechanism-based evaluation of allograft biopsy samples that can supplant routine pathology (1) . During the past decade, numerous microarray studies have begun to define the molecular phenotypes of allograft rejection (2) (3) (4) (5) (6) (7) (8) . Despite several gene sets being described and validated, none have successfully been translated into routine clinical practice. A major barrier to clinical implementation has been the requirement for dedicated fresh tissue samples, which must be specially processed and procured in addition to the standard-ofcare formalin-fixed paraffin-embedded (FFPE) biopsy samples used for histology. The consequences of this limitation are increased cost, complexity, and patient risk, as well as reduced tissue for routine histology (9) . NanoString nCounter (NanoString Technologies, Seattle, WA) is a novel gene expression platform that works reliably with FFPE tissue. It is able to analyze up to 800 customizable transcript targets per sample and is similar in sensitivity to real-time polymerase chain reaction and more sensitive than microarrays (10, 11) . The use of FFPE material allows for molecular-histological correlation on the same tissue. Cellular populations submitted for molecular testing and potential histological features of significance therefore can be better integrated than with techniques requiring separately processed tissue. Further, this technology represents the first opportunity to perform reliable retrospective gene expression testing on well-annotated archival FFPE tissue, facilitating immediate correlation with long-term clinical follow-up (1) .
We have previously demonstrated the feasibility of the NanoString system with routine FFPE tissue and have used it to assess a 34-gene set as a potential molecular diagnostic tool for antibody-mediated rejection (AMR) in human renal and cardiac allograft biopsy samples (12, 13) . Here, we apply this AMR 34-gene set to nonhuman primate (NHP) renal transplants developing chronic AMR off immunosuppression with analogous features to human renal allografts, including donor-specific antibodies (DSAs), C4d deposition, transplant glomerulopathy, and arteriopathy (14) (15) (16) (17) (18) (19) . Previous studies of protocol biopsy samples from these recipients have identified four stages of chronic AMR (16, 17) , which have subsequently been confirmed and refined in humans (20) . This study aims to use the NanoString system to validate AMRrelated transcripts from humans in a well-studied animal model representing the natural course of rejection and to determine if molecular diagnostics can enhance our understanding of the pathogenesis and evolution of AMR.
Materials and Methods

Subjects
The recipients were NHPs, Macaca fascicularis, given allogeneic bone marrow transplants (BMTs) and kidney allografts from the same donor in conjunction with transient immunosuppression. Detailed treatment protocols and outcomes have previously been published (16, 17) . In brief, the standard protocol included low-dose total body irradiation on days -6 and -5, thymic irradiation on day -1, and pretransplantation antithymocyte globulin and BMT on day 0, followed by a 1-month course of calcineurin inhibitor. Recipients after 2002 were also treated with costimulatory blockade with anti-CD154 monoclonal antibody or belatacept. In the delayed protocol, recipients initially underwent kidney transplantation alone with conventional immunosuppression, including tacrolimus, mycophenolate mofetil, and methylprednisolone, plus anti-CD8 monoclonal antibody or antithymocyte globulin. All immunosuppression was permanently discontinued 1 month after BMT in both protocols. The recipients were not treated for AMR or T cell-mediated rejection (TCMR). All surgical procedures and postoperative care were performed in accordance with National Institutes of Health guidelines for the care and use of primates and were approved by the Massachusetts General Hospital Subcommittee on Animal Research.
Samples
A total of 197 FFPE kidney samples from 81 recipients obtained between 1993 and 2013 were retrieved from the transplant pathology research tissue bank at Massachusetts General Hospital. These included 102 sequential allograft samples, consisting of protocol biopsy samples (n = 78) and postmortem samples obtained via euthanasia (n = 24), from 29 recipients in which the treatment protocol failed and chronic active AMR developed. The only selection criteria were that (1) there were two or more samples per recipient and (2) there was sufficient tissue for histology and gene expression analysis. Comparison samples included 15 normal native nephrectomies from 15 recipients and a representative collection of 80 allograft biopsy (n = 53) and euthanasia (n = 27) samples from 37 recipients with pathological diagnoses of TCMR (n = 33), borderline changes/suspicious for TCMR (n = 13), suspicious for AMR (n = 7), no pathological evidence of rejection (n = 19), polyomavirus nephropathy (n = 3), pyelonephritis (n = 2), posttransplant lymphoproliferative disorder (n = 2), and obstruction (n = 1). None of the comparison samples came from recipients that developed AMR.
Clinical data and pathology review
Treatment protocols, serum creatinine, and DSA results were retrieved. Histology slides (hematoxylin and eosin, periodic acid-Schiff, and C4d immunohistochemistry) were reviewed by at least one transplant pathologist (R.N.S., I.A.R.), and diagnoses were assigned according to the 2015 Banff classification (21) . The histological techniques have previously been described (16, 17) .
RNA isolation
A previously reported NanoString workflow was used (12) . In brief, three consecutive 20-lm sections were obtained from each FFPE block and sent to the University of Alberta. Xylene deparaffinization and RNA extraction were performed with the Ambion RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific, Waltham, MA). RNA concentration and purity were measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).
NanoString gene expression analysis
Oligonucleotide probes specific to M. fascicularis were manufactured for the mRNA sequences of 38 genes (Integrated DNA Technologies, Coralville, IA). These included a previously described AMR 34-gene set composed of 18 endothelial, six natural killer (NK) cell, and 10 inflammation-related genes, as well as four housekeeping genes (12) . Probe sequences are provided in Table S1 . Gene expression was then quantified with use of the NanoString nCounter Gene Expression assay (NanoString Technologies) as per manufacturer instructions. To assess reproducibility, eight samples were randomly selected for duplicate analysis in separate runs. Quality control assessment and normalization of raw NanoString gene expression results were performed with nSolver Analysis Software Version 3.0 (NanoString Technologies) using the manufacturer-recommended default parameters.
Retrospective analysis of human microarray data set A publicly available human cDNA microarray data set (GSE36059) was retrieved from the NCBI Gene Expression Omnibus (www.ncbi.nlm.nih. gov/geo) to compare gene set performance in human samples. The data set included gene expression results (Affymetrix Human Genome U133 Plus 2.0 Array) for 403 renal allograft indication biopsy samples with diagnostic labels of AMR (n = 65), TCMR (n = 35), mixed rejection (n = 22), and nonrejection (n = 281), as per Banff 2009 criteria (22) . The raw data files were imported and normalized with the use of BRB-ArrayTools Version 4.5.0 (23) . Mean values were used for genes with repeat data points.
Data analysis
Postnormalization statistical analysis and visualization were performed with R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria). Normalized transcript counts (NanoString data) and log intensity values (microarray data) were converted to z-scores (number of standard deviations away from the population mean for each gene) for individual gene analysis. Mean z-scores were used for aggregate gene set analysis. Gene expression and correlation heat map analyses (heatmap.2 function in gplots package) were performed with unsupervised hierarchical clustering by Euclidean distance. Spearman's rank correlation coefficients (cor function in stats package) and unsupervised principal component analysis (PCA; prcomp function in stats package) were used to characterize intervariable relationships. Mann-Whitney U-tests (wilcox.test function in stats package) were used for class comparison analyses. Receiver operating characteristic (ROC) curve analysis (roc function in pROC package) was used for assessment of diagnostic performance. Youden's J-statistic (point on ROC curve farthest from diagonal index line) was used for defining diagnostic thresholds (24) . Individual gene ranking, gene set construction, and gene set ranking were achieved with repeated 10-fold cross-validation analysis (train function in caret package) using three repeats and na€ ıve Bayes model. Values of p < 0.05 were considered statistically significant. 
Results
RNA and quality control
Individual gene expression versus diagnosis
After histological evaluation, the samples were assigned one of the following diagnostic labels according to Banff 2015 criteria: "AMR" (n = 38), "suspicious for AMR" (n = 15), "mixed rejection" (n = 27), "TCMR" (n = 41), "borderline" (n = 21), "no rejection" (n = 32), "other" (n = 8), and "normal native nephrectomy" (n = 15). Heat map analysis revealed general grouping of diagnostic categories based on individual gene expression patterns ( Figure 1 ). Sixty-seven (74%) of the 91 samples diagnosed as "normal," "no rejection," "other," "borderline," or "suspicious for AMR" clustered within the larger "No Rejection" group indicated in Figure 1 . Thirtyfive (54%) of the 65 samples diagnosed as pure AMR or mixed rejection clustered within the "AMR" group. Five (33%) of the 15 samples diagnosed as suspicious for AMR also clustered within the "AMR" group. Sixteen (39%) of the 41 samples diagnosed as TCMR clustered within the "TCMR" group. Endothelium-associated transcripts generally exhibited higher expression in the "AMR" group. Inflammation-related transcripts showed a tendency for higher expression in the "TCMR" group as well as the "No Rejection" samples with inflammatory diseases. Figure 2 represents a correlation heat map demonstrating the correlation coefficients between gene expression and Banff histology scores/DSA status. Endotheliumassociated transcripts exhibited strong correlation with DSA and traditional AMR lesions, including C4d deposition, transplant glomerulopathy (cg), glomerulitis (g), and peritubular capillaritis (ptc). Mesangial matrix expansion (mm) also correlated with endothelial gene expression. Histological lesions of chronic allograft injury, including arterial fibrous intimal thickening (cv), interstitial fibrosis (ci), and tubular atrophy (ct), clustered together and also demonstrated greater correlation with endothelial transcripts. Traditional TCMR-related lesions, including intimal arteritis (v), tubulitis (t), interstitial inflammation (i), and total inflammation (ti), exhibited the strongest correlation with inflammatory, NK cell, and interferon-c-induced transcripts.
Individual gene expression versus immunopathology
Diagnostic performance of gene expression analysis
The ability of gene expression testing to discriminate AMR from non-AMR cases, as per Banff 2015 criteria, was assessed with repeated 10-fold cross-validation ROC curve analysis. Table S2 lists the mean area under the curve (AUC), mean accuracy, and mean Cohen's j statistic between resampling repeats for each individual gene. Ranking the genes by mean AUC value, VWF was the strongest individual performer (AUC = 0.917), while CX3CR1 was the weakest (AUC = 0.435). There was general correlation between mean AUC, accuracy, and j values, particularly for the top performing genes, with VWF also demonstrating the highest mean accuracy (0.881) and j (0.728) values. Detailed diagnostic performance parameters calculated from the study set as a single cohort are also provided in Table S2 and show generally good agreement with the cross-validation results, particularly for the top performing genes.
Based on the cross-validation AUC rank order, the genes were combined into successively larger gene sets as follows: one-gene set includes VWF, two-gene set includes VWF and DARC, three-gene set includes VWF, DARC, and CAV1, . . ., and 34-gene set includes all genes. Cross-validation and study set ROC curve analyses were then repeated for each of the 34-gene sets (Table S3 ). The three-gene set demonstrated the highest AUC on both analyses (cross-validation AUC = 0.920, study set AUC = 0.916) and thus was used for subsequent analysis. Figure 3(A) shows the study set ROC curve for the three-gene set, with the following diagnostic performance parameters: AUC = 0.916, accuracy = 0.838, sensitivity = 0.862, specificity = 0.826, positive predictive value = 0.709, and negative predictive value = 0.924. The 34-gene set demonstrated the weakest diagnostic performance with cross-validation and study set AUCs of 0.679 ( Figure 3B ). The diagnostic cut-off for the threegene set, as defined by Youden's J-statistic, was a mean z-score of À0.092. The range of three-gene set values in this NHP cohort was À0.948 to 3.831 (mean = 0.000, median = À0.278), with the diagnostic threshold of -0.092 representing the 60th percentile.
A publicly available human renal allograft microarray data set (n = 403) was retrospectively analyzed to compare gene set performance in human versus NHP samples. The NHP-refined three-gene set demonstrated inferior diagnostic performance in human samples with an AUC of 0.775 ( Figure 3C ). In contrast, the complete 34-gene set exhibited superior performance in human samples with an AUC of 0.815 ( Figure 3D ). Figure 4 demonstrates AMR three-gene set (VWF, DARC, CAV1) expression versus Banff 2015 diagnoses for all 197 NHP samples. The normal native nephrectomy group showed significantly lower gene set expression than all of the other groups (p ≤ 0.001). The "AMR" and "mixed rejection" groups exhibited significantly higher gene set expression than all of the other groups (p ≤ 0.024). The "suspicious for AMR" group demonstrated significantly higher expression than the remainder of the non-AMR groups (p ≤ 0.004) with the exception of "other" (p = 0.076). The TCMR group showed significantly higher expression than the borderline group (p = 0.016) but not the "other" or "no rejection" groups. There was no significant difference in gene set expression between the "no rejection," "borderline," and "other" groups.
AMR three-gene set versus diagnosis
Thirty-four (89%) of the 38 pure AMR samples and 22 (81%) of the 27 mixed rejection samples demonstrated AMR three-gene set expression above the ROC-derived diagnostic cut-off (dashed line in Figure 4 ). Only 23 (17%) of 132 non-AMR samples (eight suspicious for AMR, six no rejection, five TCMR, two borderline, one polyomavirus nephropathy, and one pyelonephritis) exhibited gene set expression above the diagnostic threshold. Twelve (52%) of these 23 samples (five suspicious for AMR, three no rejection, two TCMR, and two borderline), associated with a total of eight recipients, had subsequent biopsy samples diagnostic for AMR an average of 356 days later (range: 23-749 days). According to Banff 2015 criteria, two of these cases (i.e. those showing isolated g1/ptc1 lesions with DSA but no C4d) would be reclassified as AMR with the inclusion of the threegene set in the diagnostic algorithm.
AMR three-gene set expression was significantly higher in C4d-positive versus C4d-negative cases (p < 0.001) as well as DSA-positive versus DSA-negative cases (p < 0.001) ( Figure 5 ). Gene set expression showed significant correlation with serum creatinine at the time of sample procurement (r = 0.152, p = 0.036). There was no significant difference in gene set expression between biopsy and euthanasia samples and no significant correlation with the number of days posttransplantation. There was also no significant difference in AMR incidence or gene set expression between standard and delayed protocol samples.
AMR three-gene set versus immunopathology AMR three-gene set expression exhibited significant correlation with AMR-related immunopathological features, including C4d deposition (r = 0.634, p < 0.001), cg (r = 0.620, p < 0.001), DSA positivity (r = 0.593, p < 0.001), g (r = 0.560, p < 0.001), and ptc (r = 0.392, p < 0.001) ( Table 1) . Correlation with ptc was seen in both mononuclear (r = 0.649, p < 0.001) and polymorphonuclear (r = 0.340, p < 0.001) subtypes. Gene set expression also correlated with chronic injury lesions, including mm (r = 0.487, p < 0.001), ci (r = 0.388, p < 0.001), ct (r = 0.336, p < 0.001), and cv (r = 0.199, p = 0.006). It did not correlate with traditional TCMR lesions including i, ti, t, and v.
PCA was used to further characterize the relationship between Banff 2015 diagnoses and gene set expression, DSA, and histology. Figure 6 demonstrates distinct separation of the diagnostic categories with principal component (PC) 1 and PC2, together accounting for 61.3% of the explained variance. PC1 primarily shows an AMR continuum from "no rejection" to "suspicious for AMR" to "AMR/mixed rejection." PC2 primarily demonstrates a TCMR continuum from "no rejection/AMR" to "borderline" to "TCMR." Overlap between mixed rejection and pure AMR is partially discriminated with both PC1 and PC2. Mixed rejection partially overlaps with pure TCMR on PC2 but not PC1. The AMR three-gene set vector is most closely oriented in the direction of the pure AMR group, indicating that it has the strongest association with this diagnostic category. A tight cluster of traditional AMR-related variables, including cg, C4d, DSA, g, and mm (in order of counterclockwise orientation), are also associated with the pure AMR group. A cluster of traditional TCMR-related lesions, including t, i, and ti, are most closely associated with the pure TCMR group. Between these two sets of more specific AMR-and TCMR-related variables lies a group of more ambiguous histological lesions, including those of chronicity (ci, ct, and cv) as well as ptc (closer to AMR) and v (closer to TCMR).
AMR three-gene set in sequential samples
The temporal pattern of AMR three-gene set expression for the 20 recipients that had at least four sequential samples is demonstrated in Figure S1 . These included 13 recipients that developed AMR, five recipients that developed TCMR only, and two recipients that did not exhibit diagnostic evidence of rejection. All of the recipients with AMR demonstrated at least one episode of increased gene set expression above the ROC-derived diagnostic threshold (indicated by the dashed line). Some of these recipients had persistently rising expression levels over time (AMR 1), while others demonstrated a transient rise followed by a decline (AMR 6). Some recipients showed relatively stable expression (AMR 13), while others were more erratic (AMR 5). Elevated gene set expression generally corresponded with the development of immunopathological evidence of AMR, but it also occasionally preceded it (AMR 12). The single ABOincompatible recipient included in the study (AMR 8) showed rapid development of AMR within the first 2 months of transplantation. Nine (69%) of the 13 AMR recipients demonstrated mixed rejection (AMR 2). Some of the euthanasia samples exhibited a sharp decline in expression (AMR 2), while others did not (AMR 7). The no rejection and TCMR only recipients generally showed Endothelial genes demonstrate the strongest correlation with lesions associated with antibody-mediated rejection (C4d, DSA, cg, g, ptc). Inflammation-related genes generally correlate with T cell-mediated rejection lesions (t, i, ti). Histological lesions associated with chronic injury (cv, ci, ct) also correlate with endothelial genes. cg, transplant glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy; cv, arterial fibrous intimal thickening; g, glomerulitis; i, interstitial inflammation; mm, mesangial matrix increase; ptc, peritubular capillary margination; t, tubulitis; TCMR, T-cell mediated rejection; ti, total interstitial inflammation; v, intimal arteritis.
consistently low levels of expression, although one from each group demonstrated transient elevation (No Rejection 2 and TCMR 2).
Discussion
There is an urgent need for improved methods of detecting and grading clinical and subclinical AMR (25) . Growing recognition of the potential diagnostic utility of gene expression testing is evidenced by its inclusion in the 2013 Banff classification (26) and its prioritization as a major focus of discussion at the 2015 Banff meeting (21) . However, obstacles to the successful translation of molecular testing into routine clinical practice include (1) lack of a true diagnostic "gold standard" for validating potential molecular diagnostics, (2) heterogeneity of existing data associated with different Banff classification iterations, (3) absence of robust validation studies, and (4) lack of consensus on platforms to be used, transcripts to be assessed, and criteria for positivity (21) .
We aimed to address these challenges by analyzing the expression of AMR-related transcripts in an animal model free from the confounding variables of inconsistent immunosuppression, rejection treatment, and patient compliance. The recipients in this study were also otherwise healthy and, thus, not complicated by the heterogeneity of medical comorbidities affecting human patients. These factors allowed for the molecular characterization of a relatively pure model for allograft rejection. Our analysis validated the molecular phenotype of AMR previously identified in humans by confirming the correlation between endothelium-associated transcripts (27) and immunopathological criteria currently used in the Banff classification for diagnosing AMR (21) . The inclusion of only AMR-related transcripts allowed for a focused evaluation of molecular testing in a specific diagnostic condition.
This study further demonstrated the technical robustness of the NanoString platform through successful analysis of old archival FFPE samples, some of which had been in storage for longer than 20 years. This confirms the The PCA results validate recent updates to the 2013 Banff classification, specifically the incorporation of gene expression testing as a potential diagnostic criterion for AMR (26) . Using current Banff criteria, two samples in the suspicious for AMR group would be upgraded to a full diagnosis of AMR with incorporation of the AMR three-gene set. PCA also highlighted the ambiguity of intimal arteritis (v lesions), peritubular capillaritis (ptc lesions), vasculopathy (cv lesions), and IFTA (ci and ct lesions) between AMR and TCMR. This confirms recent observations in human patients (28, 29) and provides further evidence for the relative nonspecificity of these lesions as well as the complex interplay between antibody-and cell-mediated pathways of injury. However, a relatively closer relationship between chronic histological lesions and AMR is consistent with antibody-mediated injury being associated with a greater degree of cumulative damage later in the posttransplantation period in this NHP model. The phenomenon of mixed rejection, with AMR often following TCMR, was identified in more than half of the AMR NHP recipients, suggesting that this represents the true natural pattern of rejection. However, PCA demonstrated closer proximity of the mixed rejection cases to AMR. Borderline and TCMR, on the other hand, appear to represent a molecular-histological continuum, as previously described in humans (30) .
The AMR three-gene set derived in this study demonstrated excellent discrimination of AMR and non-AMR pathologies (AUC = 0.92). These three genes (VWF, DARC, CAV1) are all endothelium-related transcripts with long-standing associations with AMR in humans (31) (32) (33) . Their biological functions include endothelial injury, repair, activation, and angiogenesis. Elevated endotheliumassociated transcript expression has been reported in non-AMR conditions, including acute tubular injury, TCMR, and viral and bacterial infection, although, in the absence of DSA, this has not been associated with inferior allograft survival (27) . The discrepancy in diagnostic performance between NHP and human samples, in which the complete 34-gene set performed better, may be related to differences in gene expression platforms, recipient treatment, comorbidities, and sample selection (i.e. retrospective protocol biopsies vs. prospective indication biopsies). In particular, the conditioning protocols used in this NHP model, which included BMT, irradiation, and immunosuppression weaning, differ significantly from standard clinical practice and may have contributed to gene expression discrepancies. However, most biopsy samples were taken more than 6 months posttransplantation, suggesting that the rejection seen in these animals represents failure of the conditioning protocol and, with that, the natural course of rejection given that they did not receive any specific antirejection treatment. Due to the additional confounders in humans, a larger gene set might be more applicable in the clinical setting but should likely include the three top genes identified here, as they appear to have the strongest association with a pure AMR phenotype. To successfully translate molecular transplant diagnostics into routine clinical practice, consensus must be generated on specific molecules to be assessed, methods and settings in which to assess them, and diagnostic thresholds to use. These elements can be validated in retrospective and prospective multicenter studies including standardized molecular assessment in comparable clinical contexts. The analytic approach used in this study represents a potential model for such validation studies using large archives of wellannotated human FFPE samples with long-term followup. This will enable wider application and eventual adoption of molecular transplant diagnostics as standard of care.
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